Boston Scientific Corp. is enjoying strong revenue growth in all of its business segments. Yesterday the company reported its 2016 third quarter sales, which reached $2.1 billion, thanks to an 11% increase compared to the prior year period.
According to a company release, Boston Scientific reported the following growth:
- MedSurg: 15%
- Cardiovascular: 13%
- Rhythm Management: 4%
- United States: 11%
- Europe: 6%
- Asia-Pacific, Middle East and Africa: 20%
- Emerging markets: 10%
Other noteworthy developments this quarter include the agreement to acquire EndoChoice Holdings, Inc., a company that provides products to treat gastrointestinal conditions; FDA approval of its EMBLEM MRI Subcutaneous Implantable Defibrillator; CE Mark of the LOTUS Edge Valve System (TAVR); and a $25-million in vestment in VENITI, Inc., a manufacturer of stents for chronic venous insufficiency.